Does the media favor ZVRA or CRDL?

In the previous week, Zevra Therapeutics had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Zevra Therapeutics and 4 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.87 beat Zevra Therapeutics' score of 0.81 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRDL or AQST?

In the previous week, Aquestive Therapeutics had 6 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 10 mentions for Aquestive Therapeutics and 4 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.87 beat Aquestive Therapeutics' score of 0.81 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRDL or CRMD?

In the previous week, Cardiol Therapeutics had 2 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 0.94 beat Cardiol Therapeutics' score of 0.87 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PHAT or CRDL?

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Phathom Pharmaceuticals and 4 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.87 beat Phathom Pharmaceuticals' score of 0.70 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TLRY or CRDL?

In the previous week, Tilray Brands had 27 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 31 mentions for Tilray Brands and 4 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.87 beat Tilray Brands' score of 0.42 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 12 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cardiol Therapeutics (CRDL) Competitors

$1.15 +0.01 (+0.88%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.03 (+2.61%)

As of 07:19 AM Eastern

Compare

CRDL vs. ZVRA, AQST, CRMD, PHAT, and TLRY

Should you buy Cardiol Therapeutics stock or one of its competitors? Cardiol Therapeutics's main competitors and comparable companies include Zevra Therapeutics (ZVRA), Aquestive Therapeutics (AQST), CorMedix (CRMD), Phathom Pharmaceuticals (PHAT), and Tilray Brands (TLRY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Zevra Therapeutics presently has a consensus price target of $27.14, suggesting a potential upside of 164.29%. Cardiol Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 769.57%. Given Cardiol Therapeutics' higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zevra Therapeutics has a net margin of 42.82% compared to Cardiol Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Zevra Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	5.73	$83.23M	$0.92	11.16
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Zevra Therapeutics had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Zevra Therapeutics and 4 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.87 beat Zevra Therapeutics' score of 0.81 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Summary

Zevra Therapeutics beats Cardiol Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Aquestive Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Cardiol Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Cardiol Therapeutics has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Aquestive Therapeutics	$44.54M	11.44	-$83.78M	-$0.65	N/A

In the previous week, Aquestive Therapeutics had 6 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 10 mentions for Aquestive Therapeutics and 4 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.87 beat Aquestive Therapeutics' score of 0.81 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Cardiol Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 769.57%. Aquestive Therapeutics has a consensus price target of $8.60, indicating a potential upside of 111.82%. Given Cardiol Therapeutics' higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aquestive Therapeutics beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to CorMedix?

Cardiol Therapeutics (NASDAQ:CRDL) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

In the previous week, Cardiol Therapeutics had 2 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 0.94 beat Cardiol Therapeutics' score of 0.87 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has a net margin of 40.49% compared to Cardiol Therapeutics' net margin of 0.00%. CorMedix's return on equity of 40.52% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
CorMedix	40.49%	40.52%	20.61%

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CorMedix has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
CorMedix	$457.20M	1.27	$163.05M	$2.14	3.49

Cardiol Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Cardiol Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 769.57%. CorMedix has a consensus price target of $15.00, indicating a potential upside of 101.07%. Given Cardiol Therapeutics' higher possible upside, research analysts plainly believe Cardiol Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

CorMedix beats Cardiol Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Phathom Pharmaceuticals and 4 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.87 beat Phathom Pharmaceuticals' score of 0.70 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals currently has a consensus price target of $20.67, suggesting a potential upside of 175.56%. Cardiol Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 769.57%. Given Cardiol Therapeutics' higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Phathom Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cardiol Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Phathom Pharmaceuticals' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Cardiol Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	3.46	-$221.25M	-$1.28	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Summary

Phathom Pharmaceuticals beats Cardiol Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Tilray Brands had 27 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 31 mentions for Tilray Brands and 4 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.87 beat Tilray Brands' score of 0.42 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	12 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics has lower revenue, but higher earnings than Tilray Brands. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45M	0.52	-$121.40M	-$1.40	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Tilray Brands currently has a consensus price target of $5.90, indicating a potential upside of 83.80%. Cardiol Therapeutics has a consensus price target of $10.00, indicating a potential upside of 769.57%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.38
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Tilray Brands has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -16.91%. Tilray Brands' return on equity of -10.39% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-16.91%	-10.39%	-7.38%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 1.6% of Tilray Brands shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cardiol Therapeutics beats Tilray Brands on 8 of the 14 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$135.58M	$12.46B	$7.31B	$12.93B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	-4.60	665.35	215.94	21.15
Price / Sales	N/A	933.07	625.89	104.29
Price / Cash	N/A	83.43	76.19	51.56
Price / Book	10.45	9.25	10.40	6.01
Net Income	-$24.20M	$2.84B	$3.50B	$380.68M
7 Day Performance	-6.50%	-3.82%	-3.32%	-3.16%
1 Month Performance	-39.47%	-7.00%	-6.58%	-5.20%
1 Year Performance	10.58%	-4.67%	2.68%	-4.08%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	3.443 of 5 stars	$1.15 +0.9%	$10.00 +769.6%	+6.5%	$135.58M	N/A	N/A	18	News Coverage
ZVRA Zevra Therapeutics	4.2532 of 5 stars	$10.55 -1.4%	$27.14 +157.4%	-12.8%	$628.76M	$136.07M	11.51	61	News Coverage Insider Trade
AQST Aquestive Therapeutics	1.8859 of 5 stars	$4.49 -1.7%	$9.17 +104.0%	-44.7%	$566.69M	$54.09M	N/A	147	Trending News Analyst Forecast
CRMD CorMedix	3.0076 of 5 stars	$7.19 -1.0%	$15.00 +108.8%	-29.7%	$561.17M	$311.71M	3.36	191
PHAT Phathom Pharmaceuticals	3.0456 of 5 stars	$6.58 -1.9%	$21.25 +223.2%	-44.2%	$535.57M	$239.66M	N/A	371	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDL) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. ZVRA, AQST, CRMD, PHAT, and TLRY

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Summary

How does Cardiol Therapeutics compare to Aquestive Therapeutics?

Summary

How does Cardiol Therapeutics compare to CorMedix?

Summary

How does Cardiol Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Cardiol Therapeutics compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. ZVRA, AQST, CRMD, PHAT, and TLRY

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Do analysts rate ZVRA or CRDL?

Is ZVRA or CRDL more profitable?

Which has better earnings and valuation, ZVRA or CRDL?

Do institutionals & insiders hold more shares of ZVRA or CRDL?

Does the media favor ZVRA or CRDL?

Which has more risk and volatility, ZVRA or CRDL?

Summary

How does Cardiol Therapeutics compare to Aquestive Therapeutics?

Is CRDL or AQST more profitable?

Which has better valuation & earnings, CRDL or AQST?

Does the media prefer CRDL or AQST?

Which has more volatility and risk, CRDL or AQST?

Do analysts prefer CRDL or AQST?

Do insiders and institutionals believe in CRDL or AQST?

Summary

How does Cardiol Therapeutics compare to CorMedix?

Does the media prefer CRDL or CRMD?

Is CRDL or CRMD more profitable?

Do institutionals & insiders believe in CRDL or CRMD?

Which has higher earnings and valuation, CRDL or CRMD?

Which has more risk and volatility, CRDL or CRMD?

Do analysts recommend CRDL or CRMD?

Summary

How does Cardiol Therapeutics compare to Phathom Pharmaceuticals?

Does the media favor PHAT or CRDL?

Do analysts rate PHAT or CRDL?

Which has more risk and volatility, PHAT or CRDL?

Do insiders and institutionals hold more shares of PHAT or CRDL?

Is PHAT or CRDL more profitable?

Which has better valuation & earnings, PHAT or CRDL?

Summary

How does Cardiol Therapeutics compare to Tilray Brands?

Does the media prefer TLRY or CRDL?

Which has better earnings and valuation, TLRY or CRDL?

Do analysts rate TLRY or CRDL?

Which has more volatility & risk, TLRY or CRDL?

Is TLRY or CRDL more profitable?

Do institutionals & insiders hold more shares of TLRY or CRDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools